Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221034213> ?p ?o ?g. }
- W4221034213 endingPage "5183" @default.
- W4221034213 startingPage "5149" @default.
- W4221034213 abstract "Epidermal growth factor receptor (EGFR) is of great significance in mediating cell signaling transduction and tumor behaviors. Currently, third-generation inhibitors of EGFR, especially osimertinib, are at the clinical frontier for the treatment of EGFR-mutant non-small-cell lung cancer (NSCLC). Regrettably, the rapidly developing drug resistance caused by EGFR mutations and the compensatory mechanism have largely limited their clinical efficacy. Given the synergistic effect between EGFR and other compensatory targets during tumorigenesis and tumor development, EGFR dual-target inhibitors are promising for their reduced risk of drug resistance, higher efficacy, lower dosage, and fewer adverse events than those of single-target inhibitors. Hence, we present the synergistic mechanism underlying the role of EGFR dual-target inhibitors against drug resistance, their structure-activity relationships, and their therapeutic potential. Most importantly, we emphasize the optimal target combinations and design strategies for EGFR dual-target inhibitors and provide some perspectives on new challenges and future directions in this field." @default.
- W4221034213 created "2022-04-03" @default.
- W4221034213 creator A5010007692 @default.
- W4221034213 creator A5012816264 @default.
- W4221034213 creator A5018396855 @default.
- W4221034213 creator A5019373631 @default.
- W4221034213 creator A5029436475 @default.
- W4221034213 creator A5038261237 @default.
- W4221034213 creator A5044794520 @default.
- W4221034213 creator A5046081003 @default.
- W4221034213 creator A5048352494 @default.
- W4221034213 creator A5053992124 @default.
- W4221034213 creator A5078010775 @default.
- W4221034213 creator A5081689932 @default.
- W4221034213 date "2022-03-21" @default.
- W4221034213 modified "2023-10-17" @default.
- W4221034213 title "Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy" @default.
- W4221034213 cites W1808513053 @default.
- W4221034213 cites W1881230374 @default.
- W4221034213 cites W1963826141 @default.
- W4221034213 cites W1964182986 @default.
- W4221034213 cites W1965755884 @default.
- W4221034213 cites W1966658428 @default.
- W4221034213 cites W1971160611 @default.
- W4221034213 cites W1972666742 @default.
- W4221034213 cites W1973268287 @default.
- W4221034213 cites W1975131304 @default.
- W4221034213 cites W1975692560 @default.
- W4221034213 cites W1976297982 @default.
- W4221034213 cites W1983005412 @default.
- W4221034213 cites W1983452202 @default.
- W4221034213 cites W1983523083 @default.
- W4221034213 cites W1985020816 @default.
- W4221034213 cites W1986792926 @default.
- W4221034213 cites W1987186059 @default.
- W4221034213 cites W1988827171 @default.
- W4221034213 cites W1991649432 @default.
- W4221034213 cites W1993799596 @default.
- W4221034213 cites W1998727173 @default.
- W4221034213 cites W1998971866 @default.
- W4221034213 cites W2001790582 @default.
- W4221034213 cites W2003892109 @default.
- W4221034213 cites W2009007206 @default.
- W4221034213 cites W2009196279 @default.
- W4221034213 cites W2013750047 @default.
- W4221034213 cites W2014881369 @default.
- W4221034213 cites W2015673035 @default.
- W4221034213 cites W2017236628 @default.
- W4221034213 cites W2017410521 @default.
- W4221034213 cites W2019822560 @default.
- W4221034213 cites W2020242834 @default.
- W4221034213 cites W2026863172 @default.
- W4221034213 cites W2028015151 @default.
- W4221034213 cites W2028415754 @default.
- W4221034213 cites W2030547477 @default.
- W4221034213 cites W2031494655 @default.
- W4221034213 cites W2035105910 @default.
- W4221034213 cites W2039107968 @default.
- W4221034213 cites W2039861047 @default.
- W4221034213 cites W2041993682 @default.
- W4221034213 cites W2044295369 @default.
- W4221034213 cites W2045153367 @default.
- W4221034213 cites W2045477218 @default.
- W4221034213 cites W2046626698 @default.
- W4221034213 cites W2048883883 @default.
- W4221034213 cites W2054241233 @default.
- W4221034213 cites W2054948698 @default.
- W4221034213 cites W2058620780 @default.
- W4221034213 cites W2059981607 @default.
- W4221034213 cites W2061576044 @default.
- W4221034213 cites W2062289724 @default.
- W4221034213 cites W2067538155 @default.
- W4221034213 cites W2068211485 @default.
- W4221034213 cites W2073100055 @default.
- W4221034213 cites W2075539463 @default.
- W4221034213 cites W2079677704 @default.
- W4221034213 cites W2079731436 @default.
- W4221034213 cites W2081267458 @default.
- W4221034213 cites W2085132233 @default.
- W4221034213 cites W2086778602 @default.
- W4221034213 cites W2087257002 @default.
- W4221034213 cites W2087955215 @default.
- W4221034213 cites W2094146542 @default.
- W4221034213 cites W2095201384 @default.
- W4221034213 cites W2096540669 @default.
- W4221034213 cites W2098553097 @default.
- W4221034213 cites W2099803844 @default.
- W4221034213 cites W2099915065 @default.
- W4221034213 cites W2104600818 @default.
- W4221034213 cites W2110682589 @default.
- W4221034213 cites W2111109297 @default.
- W4221034213 cites W2114796829 @default.
- W4221034213 cites W2115213382 @default.
- W4221034213 cites W2117726013 @default.
- W4221034213 cites W2122272858 @default.
- W4221034213 cites W2126709309 @default.
- W4221034213 cites W2129656399 @default.
- W4221034213 cites W2130357378 @default.